Author

Raja Atreya

Assessing ulcerative colitis: Is there something your patient isn’t telling you? (Eli Lilly and Company)
Assessing ulcerative colitis: Is there something your patient isn’t telling you? (Eli Lilly and Company)

Raja Atreya  et al.

Medical management of acute severe ulcerative colitis
Medical management of acute severe ulcerative colitis

Raja Atreya

JAK to the future: a patient-centric choice in UC (Galapagos)
JAK to the future: a patient-centric choice in UC (Galapagos)

Raja Atreya  et al.

Anti-IL23 and more
Anti-IL23 and more

Raja Atreya

BURDEN OF BOWEL URGENCY ACROSS SPECIFIC TREATMENT GROUPS AMONG CROHN’S DISEASE PATIENTS – REAL WORLD GLOBAL STUDY ANALYSES
BURDEN OF BOWEL URGENCY ACROSS SPECIFIC TREATMENT GROUPS AMONG CROHN’S DISEASE PATIENTS – REAL WORLD GLOBAL STUDY ANALYSES

Raja Atreya  et al.

BURDEN OF BOWEL URGENCY ACROSS SPECIFIC TREATMENT GROUPS AMONG CROHN’S DISEASE PATIENTS – REAL WORLD GLOBAL STUDY ANALYSES
BURDEN OF BOWEL URGENCY ACROSS SPECIFIC TREATMENT GROUPS AMONG CROHN’S DISEASE PATIENTS – REAL WORLD GLOBAL STUDY ANALYSES

COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL
COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL

Raja Atreya  et al.

Taking the long view in IBD (Janssen)
Taking the long view in IBD (Janssen)

Raja Atreya  et al.

COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL
COBITOLIMOD FOR MODERATE-TO-SEVERE LEFT-SIDED ULCERATIVE COLITIS (CONDUCT): A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL

Connecting the dots: Integrating mechanism of action into advanced treatment decisions in UC (Arena Pharmaceuticals)
Connecting the dots: Integrating mechanism of action into advanced treatment decisions in UC (Arena Pharmaceuticals)

Raja Atreya  et al.

METHOD COMPARISON STUDY OF TWO COMMERCIALLY AVAILABLE TDM TEST FOR THE MEASUREMENT OF USTEKINUMAB LEVELS
METHOD COMPARISON STUDY OF TWO COMMERCIALLY AVAILABLE TDM TEST FOR THE MEASUREMENT OF USTEKINUMAB LEVELS

Raja Atreya  et al.

A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY AND SAFETY OF INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Raja Atreya  et al.

Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)
Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)

Raja Atreya  et al.

EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY
EFFICACY OF UPADACITINIB DOSE ESCALATION IN A PHASE 3 LONG-TERM EXTENSION ULCERATIVE COLITIS STUDY

Raja Atreya  et al.

DOSE-DEPENDENT DIFFERENTIAL EFFECTS OF VEDOLIZUMAB THERAPY ON ADHESION OF REGULATORY AND EFFECTOR T CELLS
DOSE-DEPENDENT DIFFERENTIAL EFFECTS OF VEDOLIZUMAB THERAPY ON ADHESION OF REGULATORY AND EFFECTOR T CELLS

Raja Atreya  et al.

PROPENSITY SCORE ADJUSTED REAL WORLD EFFECTIVENESS OF VEDOLIZUMAB VS. ANTI-TNF IN BIOLOGIC-NAÏVE CROHN´S DISEASE PATIENTS: INDUCTION PHASE RESULTS FROM THE PROSPECTIVE, OBSERVATIONAL VEDOIBD STUDY IN GERMANY
PROPENSITY SCORE ADJUSTED REAL WORLD EFFECTIVENESS OF VEDOLIZUMAB VS. ANTI-TNF IN BIOLOGIC-NAÏVE CROHN´S DISEASE PATIENTS: INDUCTION PHASE RESULTS FROM THE PROSPECTIVE, OBSERVATIONAL VEDOIBD STUDY IN GERMANY

Raja Atreya  et al.

ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 BERGAMOT STUDY
ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 BERGAMOT STUDY

Raja Atreya  et al.

Item 1 - 17 / 17
1